APOC3, apolipoprotein C3, 345

N. diseases: 153; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0042373
Disease: Vascular Diseases
Vascular Diseases
0.020 GeneticVariation group BEFREE Second, we tested whether loss-of-function mutations in APOC3, which were associated with reduced levels of nonfasting triglycerides, were also associated with reduced risks of ischemic vascular disease and ischemic heart disease. 24941082 2014
CUI: C0042373
Disease: Vascular Diseases
Vascular Diseases
0.020 GeneticVariation group BEFREE In humans, loss-of-function mutations in APOC3 are associated with reduced plasma TG levels and reduced risk for ischemic vascular disease and coronary heart disease. 26435212 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.010 Biomarker phenotype BEFREE The present study aimed to investigate the value of apolipoproteins, including ApoA-1, ApoC-III, and ApoE, in patients with small cell lung cancer (SCLC) as potential biomarkers for diagnosis, prognosis, and cancer progression. 26996551 2016
CUI: C0202236
Disease: Triglycerides measurement
Triglycerides measurement
0.100 GeneticVariation phenotype GWASDB Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. 23063622 2012
CUI: C0202236
Disease: Triglycerides measurement
Triglycerides measurement
0.100 GeneticVariation phenotype GWASCAT Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits. 28548082 2017
CUI: C0202236
Disease: Triglycerides measurement
Triglycerides measurement
0.100 GeneticVariation phenotype GWASCAT Very low-depth whole-genome sequencing in complex trait association studies. 30576415 2019
CUI: C4476910
Disease: Thin-cap fibroatheroma
Thin-cap fibroatheroma
0.010 Biomarker phenotype BEFREE These indexes were independent predictors of the presence of TCFA (ΔApoB-48: odds ratio, 1.608; 95% confidence interval, 1.040-2.486; P=0.032; apolipoprotein C-III: odds ratio, 2.581; 95% confidence interval, 1.177-5.661; P=0.018). 29930008 2018
CUI: C1300257
Disease: Thanatophoric dysplasia, type 2
Thanatophoric dysplasia, type 2
0.010 Biomarker disease BEFREE We sequenced APOC3 3'UTR in 100 type 2 diabetic (TD2) patients with severe HTG (TG > 15 mmol/L) (HTG group) compared to 100 normotriglyceridemic patients (NTG group). 27794214 2016
CUI: C0039128
Disease: Syphilis
Syphilis
0.010 Biomarker disease BEFREE Biomarker analysis revealed three proteins (Apo-A1, Apo-CIII, CRP) that differed between syphilis and other causes. 31697216 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.080 Biomarker disease BEFREE The impact of the APOC3 SNPs on fatty liver is small and depends on visceral obesity. 21829161 2012
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.080 GeneticVariation disease BEFREE The PNPLA3, but not the APOC3 rs2854116 SNP, was associated with fatty liver but not with triglyceride levels. 22105854 2012
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.080 GeneticVariation disease BEFREE By multivariable Cox analysis, concurrent fatty liver (HR 7.27, 95% confidence interval: 1.52-34.76; P = 0.013), age, cirrhosis, and APOC3 rs2854116 TC/CC genotype (HR 3.93, 95% confidence interval: 1.30-11.84; P = 0.013) were independent factors predicting HCC development. 27547913 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.080 Biomarker disease BEFREE APOC3 neither exacerbated diet-induced adiposity nor aggravated the degree of steatosis in high fructose or high fat-fed APOC3-transgenic mice. 28115523 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.080 AlteredExpression disease BEFREE However, APOC3 SNPs, alone or in combination, were not associated with insulin resistance, altered lipid levels, liver enzymes, and with liver damage (severity of steatosis, nonalcoholic steatohepatitis, and moderate/severe fibrosis) in Italian as well as in UK patients, and in the whole cohort. 21777557 2011
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.080 GeneticVariation disease BEFREE APOC3 polymorphisms had no effect on the development of steatosis and no influence on the PNPLA3 polymorphism. 23808989 2013
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.080 GeneticVariation disease BEFREE The APOC3 rs2070666 A allele was linked to the fourth quartile of the controlled attenuation parameter values (OR 2.769, 95 % CI 1.002-7.651) in 131 subjects, and also linked to the significant histological steatosis (OR 4.986, 95 % CI 1.020-24.371), but neither to liver stiffness measurement values nor to hepatic histological activity and fibrosis in NAFLD patients. 27059980 2016
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.080 GeneticVariation disease BEFREE Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. 21663607 2011
CUI: C1858501
Disease: Spinocerebellar Ataxia 12
Spinocerebellar Ataxia 12
0.010 Biomarker disease BEFREE Altered expression of some of the proteins of interest, transthyretin, haptaglobin, apolipoprotein C-II, apolipoprotein C-III are indicative of clinical manifestations such as neuropathy, cognitive impairment and altered lipid metabolism in SCA12. 22426495 2012
CUI: C0149925
Disease: Small cell carcinoma of lung
Small cell carcinoma of lung
0.010 Biomarker disease BEFREE ApoA-1 and ApoC-III may be used as differentiating and predictive markers for SCLC. 26996551 2016
CUI: C1445957
Disease: Serum total cholesterol measurement
Serum total cholesterol measurement
0.100 GeneticVariation phenotype GWASDB Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. 23063622 2012
CUI: C0523465
Disease: Serum albumin measurement
Serum albumin measurement
0.100 GeneticVariation phenotype GWASDB Genome-wide association study identifies multiple loci influencing human serum metabolite levels. 22286219 2012
CUI: C0035309
Disease: Retinal Diseases
Retinal Diseases
0.010 Biomarker group BEFREE The apoCIII concentration also was significantly higher in the group of patients with severe retinopathy (ETDRS 10-23) compared to those with moderate (ETDRS 4-9; P<.02) or mild retinopathy (ETDRS 1-3; P<.0001). 15642486 2005
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung
0.010 Biomarker disease BEFREE To examine cancer-related allelic loss in the region between D11S940 and APOC3, we used 17 polymorphic markers and allotyped 28 lung cancer-derived cell lines and their corresponding matched lymphoblastoid cell lines. 10337999 1999
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.030 AlteredExpression group BEFREE Expression profiles of ApoA-1, ApoC-III, and ApoE in different samples were examined using immunohistochemical methods, and the expression levels were correlated with cancer types, treatment, and outcomes using chi-square and Mann-Whitney tests. 26996551 2016
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.030 GeneticVariation group BEFREE apoC-III associated with apoB, apoAI, and Lp(a) (apoCIII-apoB, apoCIII-apoAI, and apoCIII-Lp(a), respectively) were measured using high-throughput chemiluminescent enzyme-linked immunoassays in 2711 subjects (1879 controls and 832 cases with CAD) in the European Prospective Investigation into Cancer and Nutrition-Norfolk prospective population study with 7.4 years of follow-up. 30249512 2019